WuXi Biologics/药明生物

Technology Spotlight: Developing therapeutic bispecific antibodies (bsAb)? By using the WuXiBody technology platform you can expedite and optimize the bsAb engineering and reduce CMC development timelines. In addition, the platform can dramatically decrease your manufacturing costs. Let's get started. To learn more, please visit: https://lnkd.in/eqZr6J3z #antibodies #drugdevelopment #bispecificantibody #antibodyengineering #antibodydiscovery #antibodydevelopment

To meet all your preclinical and late-stage bioconjugate process development needs, WuXi XDC provides state-of-the-art technologies, world-class expertise and vast hands-on experience. Access our process development capabilities to discover how WuXi XDC can help advance your bioconjugate to next milestone!

Proud Team Spotlight! Welcome to the heart of WuXi Biologics Ireland's hiring process! Our Talent Acquisition Team is more than just recruiters—they are dedicated individuals passionate about connecting exceptional talent with opportunities that drive our mission forward in the biopharmaceutical industry.   Get to know the people who are shaping the future of WuXi Biologics Ireland through innovative and strategic recruitment. Jennifer G. - Ireland's Talent Acquisition Lead, known for her strong leadership, proactive support, and extensive knowledge of the biopharmaceutical industry and Talent Acquisition area. Jennifer is a role model, inspiring her team with her dedication and expertise.   Brenda McEvoy - A forward-thinking Talent Acquisition Business Partner, Brenda ensures efficiency and organisational excellence, and is known for her team-oriented approach.   Eimear Forde - A resilient strategist in Talent Acquisition, Eimear promotes collaboration and empathy, building strong partnerships and being candidate-focused.   Gavin Poland - A data-driven and strategic thinker, Gavin is result-driven and a clear communicator, using insights for recruitment strategies and problem-solving.   Rebecca Walsh - The backbone of the team, Rebecca handles data meticulously, provides steadfast support, and ensures swift coordination throughout processes.   Paul Hollen - The EU Talent Acquisition Lead, Paul brings extensive experience in Talent Acquisition and a deep knowledge of the industry. He has a knack for employer branding, enhancing visibility and reputation in the competitive marketplace. Each member of our team brings a unique blend of expertise and dedication, ensuring that WuXi Biologics Ireland attracts and retains top-tier professionals in the biopharmaceutical industry. Together, they are advancing biopharmaceutical innovation right here at WuXi Biologics Ireland! WuXi Biologics Xiaoyu Xie Brendan McGrath Yangyang (Allen) Wang Gene Russell Eimear McCarron Caoimhe Mc Grath Mary Dunne Funmilayo Obadeyi Susan, Yanmeng Zhang Nick Yin WuXi Vaccines Alison Byrne Zhenjie (Jay) Bi Niamh Byrne (Rooney) Seán Gaynard David Neasy Marissa O'Connell Eamonn Kelly Clare Liddy MBS (HRM), BA (Hons) John McDonnell Georgia Bartropp #TalentAcquisition #Biopharmaceutical #WuXiBiologicsIreland

Facility Spotlight: Let us help you realize your breakthrough biological treatment from concept to clinical trials and beyond, discovered, developed and manufactured here in the United States. Learn more about our U.S.-based facilities and pilot and GMP manufacturing capabilities for monoclonal and bispecific antibodies and other recombinant proteins produced from mammalian cell culture! https://lnkd.in/eHpfQTPT #biomanufacturing #gmpmanufacturing #biopharmaceutical #drugdevelopment #drugmanufacturing #mammalian #cellculture

In Case You Missed It: "Advanced Analytical Strategies: From Protein Structure Characterization to Potency Assessment for Challenging Biologic Modalities" In the rapidly evolving landscape of biologics, especially for new modalities like antibody drug conjugates (ADCs) and bispecific/multi-specific antibodies, detailed product characterization evaluation and appropriate potency assessment are crucial for ensuring product quality control and fulfilling regulatory requirement. Our webinar features two engaging topics: Deciphering Protein Structure: Advancing Biologics Development by Product Characterization and Revealing the Biologics Efficacy: Advanced Strategies for Potency Assay Development for Multi-Specific Drugs. View on demand: https://lnkd.in/eWHxA3vg

Ever wonder what it's really like to work at WuXi Biologics? Starting this week we're kicking off a new series where you get to meet the amazing people behind WuXi Biologics. Take a sneak peak at the diverse roles that make our company thrive as leaders in the life science industry. Interested in working for WuXi Biologics? Apply for a role today: https://lnkd.in/dic6JYBu #Careers #JobFairy

Technology Spotlight: WuXi Biologics’ next generation manufacturing platform WuXiUI™, introduces an improved seed train intensification process, proprietary cell culture media specially formulated for intensification processes, and process analytical technologies (PAT) with Raman-based algorithms to generate 3 to 6-fold higher cell culture productivity than traditional fed-batch processes. WuXiUI obtains 10-25 g/L titers to help drive down commercial-scale manufacturing cost of goods by 60-80% to $40-$80/g – making it the ideal solution for scale-out manufacturing strategies using disposable bioreactors. To learn more, please visit: https://lnkd.in/gghDHjwC #bioprocessing #biomanufacturing #ultraintensified #fedbatch

Service Spotlight: WuXi Biologics offers various integrated antibody discovery platforms for the generation of novel high-potency antibody therapeutics. Each project is tailored to best suit your technical and budget requirements. Learn more: https://lnkd.in/et4RwDja #antibodygeneration #antibodydiscovery #drugdevelopement #biologics

We are proud to share that WuXi Biologics has been named as a constituent company of the FTSE4Good Index Series for the fourth consecutive year. Inclusion in the FTSE4Good Index Series is based on independent analysis of data from over 8,000 securities in 47 developed and emerging countries. Over the past years, WuXi Biologics has realized substantial improvements in its overall FTSE Russell ESG score, as well as its theme scores. The company’s ESG score in 2024 achieved the top 7% in its industry. #ftse4good #CRDMO #Biomanufacturing #biopharma #sustainability #ESG Learn more about the details: https://lnkd.in/e9c4FHhQ

Are you addressing biologics risks early enough? Listen to our new podcast "The Importance of Evaluating Developability in Antibody Discovery Stage"! https://lnkd.in/eBpEq5fU In this podcast, recorded by and featured on the Cell Culture Dish Blog, we spoke with Dr. George Wang, Vice President of Discovery and Preclinical Services at WuXi Biologics, where he shares insights on the critical role of developability assessments in antibody therapeutics discovery. Dr. Wang defines developability and its role in achieving scalable production during CMC development, crucial for large-scale manufacturing prior to clinical trials. He then emphasizes the importance of identifying and addressing developability concerns early in the discovery stage to mitigate risks and ensure cost-effective development. Dr. Wang underscores that assessing developability can uncover issues with product aggregation, stability, solubility, or manufacturing efficiencies. #developabilityassesment #antibodydiscovery #antibodydevelopment #drugdiscovery #therapeuticsdiscovery #preclinicalstudies #cmcdevelopment #podcast